ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Hits A Phase 3 Milestone, Is The Stock Still Cheap?
Sanofi (ENXTPA:SAN) is back in focus after reporting that Nexviazyme met all primary and secondary endpoints in the Baby-COMET phase 3 study for infantile-onset Pompe disease, with infants alive and free of invasive ventilation at 52 weeks.
See our latest analysis for Sanofi.
At a share price of €75.08, Sanofi has seen short term share price momentum soften. The 90 day share price return is down 9.4%, the 1 year total shareholder return is down 4.6%, and the 5 year total shareholder return is...